

CORRECTED VERSION

(19) World Intellectual Property Organization International Bureau



(10) International Publication Number WO 2020/176654 A8

(43) International Publication Date 03 September 2020 (03.09.2020)

(51) International Patent Classification:

A61K 31/4375 (2006.01) A61P 35/00 (2006.01)
A61K 31/519 (2006.01) C07D 471/04 (2006.01)

(21) International Application Number:

PCT/US2020/019944

(22) International Filing Date:

26 February 2020 (26.02.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/811,432 27 February 2019 (27.02.2019) US
62/819,204 15 March 2019 (15.03.2019) US
62/825,667 28 March 2019 (28.03.2019) US
62/840,254 29 April 2019 (29.04.2019) US
62/871,694 08 July 2019 (08.07.2019) US
62/885,055 09 August 2019 (09.08.2019) US
62/901,142 16 September 2019 (16.09.2019) US
62/931,043 05 November 2019 (05.11.2019) US
62/975,088 11 February 2020 (11.02.2020) US

(71) Applicant: MADERA THERAPEUTICS, LLC [US/US]; 309 Schubauer Drive, Cary, NC 26513 (US).

(72) Inventor: IWANOWICZ, Edwin; 309 Schubauer Drive, Cary, NC 26513 (US).

(74) Agent: MOYER-HENRY, Kari; Lewis Kohn & Walker LLP, 15030 Avenue of Science, Suite 201, San Diego, CA 92128 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: USE OF CASEINOLYTIC PROTEASE P FUNCTION AS A BIOMARKER OF DRUG RESPONSE TO IMPRIDONE-LIKE AGENTS

Figure 1: Kinetics of ClpP activity without pre-incubation with ONC201 and Ex. 51 (TR57)



(57) Abstract: Use of caseinolytic protease P (ClpP) function and/or concentration as a biomarker for predicting the response of a neoplastic disease, preferably cancer or another disease where enhancing ClpP activity may provide a therapeutic benefit, to a compound of Formula I. In other aspects it relates to methods and kits, as well as methods of treatment involving the use of the biomarker.

WO 2020/176654 A8

(48) Date of publication of this corrected version:

08 October 2020 (08.10.2020)

(15) Information about Correction:

see Notice of 08 October 2020 (08.10.2020)